Press Releases Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 00:00:02 14/02/2026 +03			5-day change	1st Jan Change
243.45 ^USD	-0.45%		+1.44%	+17.64%

02-13	Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial	RE
02-13	Pennsylvania jury finds Johnson & Johnson liable for woman's ovarian cancer - attorney for national talc plaintiffs	RE

Press Releases

02-14	Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial	BU
02-12	Johnson & Johnson : Annual Report for Fiscal Year Ending December 28, 2025 (Form 10-K)	PU
02-11	BostonGene Announces Strategic Collaboration to Optimize Treatment Sequencing and Patient Tolerability in Multiple Myeloma	AQ
02-10	Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference	BU
02-09	Johnson & Johnson's Texas Two‑Step: A Bankruptcy Strategy Under Scrutiny	AQ
02-07	Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium	BU
02-06	Johnson & Johnson Releases Report on Surgeon Burnout as More than 40% Surveyed Consider Leaving the Profession	AQ
02-04	Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference	AQ
02-03	Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile	AQ
02-03	Johnson & Johnson : Highlights New Scientific Evidence and Reinforces its Leadership with Portfolio Advancements at AF Symposium	PU
02-03	Johnson & Johnson : Releases Report on Surgeon Burnout as More than 40% Surveyed Consider Leaving the Profession	PU
02-03	Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference	BU
02-02	Johnson & Johnson receives CHMP positive opinion for AKEEGA for the treatment of patients with metastatic hormone-sensitive prostate cancer with BRCA1/2 mutations	AQ
01-30	Johnson & Johnson : receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations	PU
01-27	DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible	PR
01-27	Johnson & Johnson named a 2026 Fortune World's Most Admired Company; The company made the prestigious list for the 24th consecutive year	AQ
01-27	Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile	BU
01-23	Johnson & Johnson : 4Q25 Other Financial Disclosures	PU
01-22	What you need to know about Johnson & Johnson's fourth-quarter and full-year 2025 earnings report; Check out this infographic breakdown of the company's full-year performance, with highlights from its Innovative Medicine and MedTech businesses.	AQ
01-21	Johnson & Johnson : Fourth Quarter 2025 Earnings Presentation	PU
01-21	Johnson & Johnson : 2025 Fourth-Quarter Infographic & Earnings Presentation	PU
01-21	Johnson & Johnson : Fourth Quarter 2025 4Q25 Other Financial Disclosures	PU
01-21	Johnson & Johnson : 2025 Fourth-Quarter Press Release & Supplemental Schedules	PU
01-21	Johnson & Johnson reports Q4 and Full-Year 2025 results	BU
01-15	Johnson & Johnson - TECVAYLI monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

J&J CFO Wolk on Orthopedics Spinoff, Earnings, Drug Pricing

October 14, 2025 at 07:20 pm

Johnson & Johnson: A Dose of Resilience Amid Trade Tensions

April 15, 2025 at 04:53 pm